Lack of pharmacokinetic drug–drug interaction between ramucirumab and irinotecan in patients with advanced solid tumors

被引：0
|
作者：
Ding Wang
Fadi Braiteh
James J. Lee
Crystal S. Denlinger
Dale R. Shepard
Archana Chaudhary
Yong Lin
Ling Gao
Christopher Asakiewicz
Federico Nasroulah
Patricia LoRusso
机构：
[1] Henry Ford Hospital,
[2] Comprehensive Cancer Centers of Nevada,undefined
[3] University of Pittsburgh School of Medicine,undefined
[4] Fox Chase Cancer Center,undefined
[5] Cleveland Clinic,undefined
[6] Eli Lilly and Company,undefined
[7] Eli Lilly and Company,undefined
[8] Yale Cancer Center,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2016年 / 78卷
关键词：
Pharmacokinetics; Drug–drug interactions; Ramucirumab; Irinotecan; SN-38; FOLFIRI;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：727 / 733
页数：6
相关论文
共 50 条
  • [41] Pharmacokinetic drug-drug interaction study between raltegravir and citalopram
    Blonk, Maren I.
    Langemeijer, Charlotte C. A.
    Colbers, Angela P. H.
    Hoogtanders, Karin E. J.
    van Schaik, Ron H. N.
    Schouwenberg, Bas J. J. W.
    ANTIVIRAL THERAPY, 2016, 21 (02) : 143 - 152
  • [42] Absence of pharmacokinetic drug-drug interaction between telbivudine and tenofovir
    Zhou, Xiao-Jian
    Pietropaolo, Keith
    Becker, Maya
    Ke, June
    Brown, Nathaniel A.
    GASTROENTEROLOGY, 2007, 132 (04) : A766 - A766
  • [43] No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidone
    Richeldi, Luca
    Fletcher, Sophie
    Adamali, Huzaifa
    Chaudhuri, Nazia
    Wiebe, Sabrina
    Wind, Sven
    Hohl, Kathrin
    Baker, Andrew
    Schlenker-Herceg, Rozsa
    Stowasser, Susanne
    Maher, Toby M.
    EUROPEAN RESPIRATORY JOURNAL, 2019, 53 (01)
  • [44] Pharmacokinetic drug–drug interaction between olaparib and apixaban: a case report
    M. Berge
    J. S. Giraud
    S. De Percin
    A. Puszkiel
    A. Thomas-Schoemann
    B. Blanchet
    Cancer Chemotherapy and Pharmacology, 2024, 93 : 519 - 521
  • [45] DRUG-DRUG INTERACTION (DDI) STUDY BETWEEN THE INVESTIGATIONAL NAE INHIBITOR PEVONEDISTAT (TAK-924) AND FLUCONAZOLE OR ITRACONAZOLE IN PATIENTS WITH ADVANCED SOLID TUMORS.
    Faessel, H. M.
    Harvey, R. D.
    Lockhart, A. C.
    Bauer, T. M.
    Wang, L.
    Sedarati, F.
    Santillana, S.
    Nemunaitis, J. J.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2016, 99 : S97 - S97
  • [46] Phase I and pharmacokinetic study of IHL-305 (PEGylated liposomal irinotecan) in patients with advanced solid tumors
    Infante, Jeffrey R.
    Keedy, Vicki L.
    Jones, Suzanne F.
    Zamboni, William C.
    Chan, Emily
    Bendell, Johanna C.
    Lee, Wooin
    Wu, Huali
    Ikeda, Satoshi
    Kodaira, Hiroshi
    Rothenberg, Mace L.
    Burris, Howard A., III
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (05) : 699 - 705
  • [47] A drug-drug interaction study of capecitabine and celecoxib in patients with advanced solid malignancies.
    Ramirez, Jacqueline
    House, Larry
    Karrison, Theodore G.
    Janisch, Linda A.
    Turcich, Michelle
    Salgia, Ravi
    Ratain, Mark J.
    Sharma, Manish
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [48] Phase I and pharmacokinetic study of irinotecan and docetaxel in patients with advanced solid tumors: Preliminary evidence of clinical activity
    Adjei, AA
    Klein, CE
    Kastrissios, H
    Goldberg, RM
    Alberts, SR
    Pitot, HC
    Sloan, JA
    Reid, JM
    Hanson, LJ
    Atherton, P
    Rubin, J
    Erlichman, C
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (05) : 1116 - 1123
  • [49] Phase I/II clinical and pharmacokinetic study of ecubectedin in combination with irinotecan in patients with selected advanced solid tumors
    Torralvo, A. Gil
    Vieito, M.
    Martinez Perez, J.
    Pretelli, G.
    Martinez, V.
    Boggio, G. F.
    Fernandez, C. M.
    Hernandez, A.
    Cristoveanu, E.
    Belgrano, A.
    Kahatt, C.
    Fudio, S.
    Nieto, A.
    Redondo, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S508 - S508
  • [50] Lack of pharmacokinetic drug interaction between rosiglitazone (BRL 49653C) and metformin.
    DiCicco, R
    Allen, A
    Jorkasky, D
    Carr, A
    Freed, M
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 63 (02) : 155 - 155
12345